Abstract
1056 Background: The aim of the study was to perform a comprehensive analysis of breast cancer patients with brain metastases and to compare survivals depending on biological subtype and RPA RTOG prognostic class. Methods: The group of 222 consecutive breast cancer pts with brain metastases treated in one institution in the year 2003–2006 was analyzed. Clinical characteristics and survivals were analyzed in the entire group, in 3 RPA RTOG prognostic classes and in 3 biological subgroups formed based on the level of estrogen (ER), progesterone (PR) and HER2 receptors as follow: triple-negative (ER-, PR-, HER2-), HER2-positive (HER2+++ in IHC or HER2 amplification) and ER and/or PR(+) HER2(-) breast cancer. The following factors were analyzed in a Cox model in order to identify factors influencing survival from brain metastases: initial TNM stage, histological type and grade, visceral metastases, RTOG prognostic class, biological subtype and systemic treatment after WBRT. Results: The proportion of pts with triple-negative, HER2-positive and ER/PR positive HER2-negative breast cancer pts was 57 (28%), 109 (53%) and 39 (19%), respectively. Median survival calculated from brain metastases in biological subgroups was as follows: triple-negative - 3.7 months, HER2-positive - 9 months and ER/PR positive HER2-negative - 15 months (p=0.015). Median overall survival in 3 subgroups was 2.8, 4.3 and 5.4 years, respectively (p=0.025). Median survival from brain metastases in RPA RTOG I, II and III prognostic class was 15, 11 and 3 months (p=0.0000) and in pts with and without systemic treatment after WBRT - 11 and 3 months, respectively (p=0.0001). Cox multivariate analysis revealed RPA RTOG prognostic class (HR=3.4), visceral metastases (HR 1.4) and systemic treatment after WBRT (HR =0.59) as the most important factors influencing survival calculated from brain metastases. Conclusions: Patients with brain metastases are a heterogenous group with a different outcome. In triple-negative breast cancer pts the shortest survival was observed. Poor performance status, visceral metastases and lack of systemic therapy after WBRT were the most important factors worsening survival. No significant financial relationships to disclose.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
